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ABSTRACT 
In order to accelerate the isolation and characterisation of structurally new or novel secondary 
metabolites, it is crucial to develop efficient strategies that prioritise samples with greatest 
promise early in the workflow so that resources can be utilised in a more efficient and cost-
effective manner. We have developed a metrics-based prioritisation approach using exact LC-
-HRMS which uses data for 24,618 marine natural products held in the PharmaSea database. 
Each sample was evaluated and allocated a metric score by a software algorithm based on the 
ratio of new masses over the total (sample novelty), ratio of known masses over the total 
(chemical novelty), number of peaks above a defined peak area threshold (sample complexity), 
and peak area (sample diversity). Samples were then ranked and prioritized based on these 
metric scores. To validate the approach, 8 marine sponges and 6 tunicate samples collected 
from the Fiji Islands were analysed, metric scores calculated and samples targeted for isolation 
and characterisation of new compounds. Structures of new compounds were elucidated by 
spectroscopic techniques, including 1D and 2D NMR, MS and MS/MS. Structures were 
confirmed by Computer Assisted Structure Elucidation methods (CASE) using the 
ACD/Structure Elucidator Suite. 
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Natural products have been our most productive and valuable source of new drugs to date.1,2 
For example, 70% of small molecule therapeutics to treat infectious disease, and 77% of  small 
molecules to treat cancer can trace their origin back to natural products.1 The number is 
expected to increase as drug discovery from new ecological niches and microbial sources,3–7 
and genome mining8 is now being realised. Natural products are much more attractive as drug 
leads, as they are known to occupy a much wider chemical space9,10 and are more drug-like 
than compounds derived from combinatorial chemistry.11,12 However, finding new natural 
products is far from trivial and one of the reasons for this, is the large number of known natural 
products that now stands at more than 300,000.13 This, unfortunately leads to higher rates of 
compound redundancy if chemical dereplication which is the process of compound 
identification is not performed early on in the project.14,15 Historically, natural product sources 
were usually chosen either randomly or on the basis of their ecology/geography and/or 
taxonomy. This meant determination of chemical diversity, which usually occurred after 
extraction, isolation and purification had been performed, resulted in high redundancy rates. 
To overcome this problem, several dereplication methods have been developed.13,16 One 
example is the use of genetic information of the organism17 particularly in 
microorganisms.8,13,18,19 However, challenges remain as it has been shown that even strains 
with similar 16S gene sequences do not necessarily produce the same chemistry20,21 indicating 
that the induction and/or activation of biosynthetic machinery for natural product production 
is far more complex than originally thought, and relies on a complex interaction of 
environmental, chemical, biochemical and biological stimuli.8,22 Even if the organism’s 
metabolome is successfully stimulated, the next challenge is detection and identification of 
new secondary metabolites that are often produced in small quantities, in a background of 
known metabolites present in higher quantities. It is therefore imperative to devise new 
strategies that rapidly identify known compounds early on in the project, so that resources can 
be concentrated only on the discovery of structurally new or novel ones. At the forefront of this 
chemical dereplication process is the use of LC hyphenated with detectors like MS,23,24 
photodiode array (DAD),23 evaporative light scattering (ELSD),25 and NMR.26 Recently, we 
proposed a new strategy of identifying known microbial natural products utilising a 
combination of HRMS and predicted LC retention time of 5,098 compounds from 
Streptomyces.27 Another approach used a predicted 13C NMR chemical shifts database  to 
screen for similar compounds in an extract.28  
The goal of this study was to develop a LC-HRMS-database-software-integrated tool that can 
process, screen, and prioritise samples based on three metrics: novelty, complexity and 
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diversity. To demonstrate the effectiveness of this approach we analysed 14 marine sponge and 
tunicate extracts, ranked them based on software-derived metrics followed by isolation and 
structure elucidation of compounds using HPLC, NMR and MS. The use of HRMS,20,23,29,30 
and NMR13,31,32 have been well documented as chemical dereplication tools in the literature, 
but the use of a software algorithm approach that provides numerical scores on key compound 
indicators like novelty, diversity and complexity has yet to be explored. This approach has the 
potential to vastly improve the productivity of natural products drug discovery programmes; 
particularly those involving large sample numbers. 
 
Results and Discussion 
An LCMS profile of a bacterial culture extract for example, provides m/z values corresponding 
to the metabolome of the strain under defined experimental conditions. This concept has been 
successfully utilised to characterise, identify, and discriminate samples.15,27,33 In this context, 
the data processing algorithm, ACD/IntelliXtract (IX), part of the ACD/MS Workbook Suite34 
was scripted to provide metrics on sample novelty (number of unidentified m/z ions over the 
total number of detectable ions), chemical novelty (total number of identified masses in the 
sample over the total number of ions), sample complexity (number of peaks above a defined 
threshold), and sample diversity (abundance) taking into consideration peak areas and heights. 
The script has been written for execution at the tail end of the normal LCMS data processing 
sequence which normally occurs in a series of steps starting with file conversion, followed by 
feature detection, normalisation, and finally linking with external databases for compound 
identification.35,36 A couple of software packages are currently available that can successfully 
perform these tasks. For example MZmine,37,38 XCMS,39,40 MAVEN,41 and the ACD/MS 
Workbook Suite.34 We preferred the commercially available software package provided by 
ACD/Labs, as it offered more flexibility and versatility allowing database creation and search 
capabilities (SpectrusDB), NMR data processing, NMR chemical shift prediction and structure 
elucidation (Structure Elucidator), retention time prediction (ChromGenius), and others that 
use the same interface.34 Two databases were created for identifying the masses (m/z) generated 
by IntelliXtract. PharmaSeaDB (Created using the ACD/Spectrus Enterprise platform) is a 
database of 24,618 compounds derived from MarinLit42 containing structures, molecular 
formulas, [M+H]+, [M-H]-, M+ and M- (Figure S28). The second database, MatrixDB 
containing more than one thousand compound masses (m/z) derived from culture media, 
solvent blanks and other contaminants is stored within the Postgre-SQL server.34 There is 
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flexibility in the use of other matrix databases depending on application, for example, use of 
fungal culture media instead of bacteria. Dereplication starts by inputting the LCMS data file 
name (Figure S23) and the data file processed by the scripted IX (IX.mcr) resulting in a table 
of indexed masses (Table S24), which are then deconvoluted in terms of retention time and 
percentage total ion chromatogram (%TIC, Table S25). These indexed masses are then 
screened against the two databases (MatrixDB and PharmaSeaDB (Figure S28)), yielding a 
table (Table S26) of new masses (masses not identified in either database). All this information 
is used to calculate the prioritisation metrics (Table S27). The ‘media fraction’ metric provides 
an indication of how clean the sample is from external contaminants. It is calculated by dividing 
the number of matrix ions found in the sample over the total number of ions detected. The 
‘sample novelty’ metric is the ratio of new masses to the total masses after the exclusion of 
matrix components. Samples with high sample novelty indices (Table S27) indicate low ‘hit’ 
rates in PharmaSeaDB. ‘Sample complexity’ is based on the number of new peaks above a set 
peak area threshold, within the retention time window. Samples with high complexity indices 
suggest large number of new masses either close together or spread out within the 
chromatogram. The ‘sample diversity’ metric indicates the intensity of peaks based on the sum 
of peak heights, multiplied by the logarithm of the peak areas of the new masses.  
 
Figure 1.  Metric score calculation work-flow. HR-LCMS data is loaded and processed 
by ACD/IntelliXtract (IX.mcr) that interrogated both MatrixDB and PharmaSeaDB yielding 
data for calculation of novelty, complexity, diversity and media score metrics. All metric data 
and ion chromatograms are stored in the PharmaSeaDB (Figure 2). Other information such as 
total detected peaks (m/z), new peaks and associated retention times, peak areas, and peak 
heights are automatically saved as text files. 
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Screening of compounds in MatrixDB and PharmaSeaDB was performed based on the 
principle of mass-matching43,44 with an error setting of  0.0025 Da between experimental 
HRMS data (accurate masses) and exact masses of known compounds held in the databases. 
Data processing settings used by ACD/IntelliXtract (IX.mcr) were optimised using LC-HRMS 
data of bacteria and marine sponge extracts, that had been pre-cleaned using solid phase 
extraction (SPE) to minimise ion matrix interference within the ion source of the mass 
spectrometer45,46 (Figure S35). Optimization of processing settings is important, as it affects 
the peak-picking, alignment, and data accuracy of the applied algorithm, particularly in 
complex biological samples.47,48 Each of the 14 samples (Table S38) used in this study was 
fractionated by SPE to yield four fractions (56 fractions in total), analysed by LC-HRMS, 
processed, and metric calculations performed. Samples were then ranked based on these 
metrics for isolation of compounds for structure elucidation. 
 
Figure 2.  An example of a typical output profile showing total ion chromatogram (TIC), 
sample information, and metric data (complexity, novelty, diversity, and media) stored in 
ACD/Spectrus DB - PharmaSeaDB. A sample novelty metric score of 0.34 for example 
indicates that 34% of the compounds in the sample are not found in PharmaSeaDB. A media 
fraction metric score of 0.037 indicates 3.7% of peaks in the sample originate from the matrix. 
Sample Prioritisation. Detailed analysis was carried out to determine the accuracy of the 
metric scores. Eden-6-50, the second highest ranked sample (Table S27) based on sample 
novelty showed 97 out of 109 detected masses (Tables S30, S31) were not found in 
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PharmaSeaDB, yielding a sample novelty index of 0.89 (Figure S29) or approximately 89% of 
the compounds in this sample were not found in PharmaSeaDB. In comparison, Tavarua-2-
SPE-50 (Tables S32, S33) ranked 56th overall, showed 11 masses out of 74 were not found in 
PharmaSeaDB (Sample novelty = 0.15, Figure S34) indicating about 15% of the compounds 
in this sample were not in the database. It needs to be pointed out that some masses could be 
annotated more than once depending on the charged adducts that have been formed including 
[M + Na]+, [M + NH4]
+, [2M + H]+ which could distort the results. Adduct formation varied 
between samples in this study, where some had none to some with about 10% of masses 
occurring as other adducts. Adduct formations are very difficult to predict as they are highly 
dependent on MS ion-source settings, solvents used, and analyte concentration.23,49 In addition 
some molecular ions masses may be lost due to in source fragmentations.50 
Sample novelty metric scores were ranked in decreasing order from Tavarua-8-100 to Tavarua-
2-50 (Figure 3, Table S27). Further analysis of this data tends to suggest a possible association 
of sample novelty with compound polarity, where most of the new compounds were found in 
the medium to less polar fractions (Figure 4). Sample complexity and diversity metrics are 
shown in Tables S36 and S37 respectively. Analysis of matrix contamination (media fraction 
metric) indicate it is insignificant for these marine extracts (<10% of total masses, Table S27). 
Overall, an ideal sample is one that scores high in sample novelty, complexity and diversity, 
but low in chemical novelty (indication of known compounds), and media components. 
However, this is often not straightforward as exemplified by Tavarua-8-100 which was ranked 
1st on sample novelty (Table S27), 25th on complexity (Table S36), and 15th on diversity (Table 
S37). This makes the task of sample prioritisation challenging, but because isolating 
structurally new or novel compounds was the main goal of this study, the sample novelty metric 
was given more weight than the others. To determine if the predictions by these metrics would 
yield new compounds, two samples were chosen, one from either end of the sample novelty 
metric scale for isolation and structure elucidation work. 
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Figure 3.  Sample novelty metric scores of 56 fractions in decreasing order calculated as 
the ratio of compounds not found in PharmaSeaDB against the total number of masses found 
per sample. Samples with higher novelty metric scores suggest presence of a large number of 
compounds not found in PharmaSeaDB. 
 
Figure 4. Association of new compounds (not found in PharmaSeaDB) with fraction-
types based on analysis of sample novelty scores greater than 0.50 where about 50% of the 
compounds are expected to be new. 
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Case Study 1 – Tavarua-8. This case study describes the isolation of two new compounds 
from the highest ranked fraction, Tavarua-8-100 based on the sample novelty metric. Tavarua-
8 was collected from a reef on the island of Tavarua (17.850 S, 177.183 E), Fiji Islands, and 
identified to genus level as either Eudistoma (Polycitoridae) or Pseudodistoma 
(Pseudodistoma) based on detailed morphological and molecular analysis (Supporting 
Information Part C). A voucher specimen (USP12339) has been deposited at the South Pacific 
Regional Herbarium, University of the South Pacific, Suva, Fiji. This sample was fractionated 
by SPE using 100% MeOH to yield the fraction Tavarua-8-100. The high sample novelty 
metric (0.93, Table S27) indicated a significant number (93%) of compounds in this fraction 
were not found in PharmaSeaDB and were potentially new (Figure S41, Table S42). Targeted 
purification by reversed-phase HPLC based on UV profile and LC retention time of the 
unknown compounds yielded two new eudistomin derivatives 1 (1.4 mg), and 2 (0.9 mg. Yields 
of other unknown compounds were below the detection limit for NMR spectroscopy and their 
structures remain undetermined. 
 
 
Table 1.   NMR Spectroscopic Data (600/150 MHz, CD3OD) for Compounds 1 and 2 
                                                                1                               2 
Pos. Ca, type H (J in Hz) 
 
 
COSY 
 
HMBC  
1H →13C Ca, type H (J in Hz) 
 
 
COSY 
 
HMBC  
1H →13C 
1 138.1, C     60.3, CH 3.30, ovlp   
3 139.1, CH 8.47, d (5.4) 4 1, 4a, 4b, 9a 45.3, CH2 3.30, ovlp 
3.09, dd (15.4, 4.2) 
4 4a 
4 116.5, CH 8.15, d (5.4) 
 
3 
 
3, 4a, 4b, 9a 16.1, CH2 2.60, dd (15.4, 4.2) 
2.99, ovlp 
 
3 
 
9a 
10 
 
Ovlp = overlap 
aCarbons extracted from 2D NMR (HSQC and HMBC) data 
 
Compound 1 (eudistomin Z1) showed a HRESIMS ion at m/z 407.9702 [M+H]+ (Δ 0.8 ppm) 
(Figure S15) for the expected molecular formula of C16H15Br2N3, and requiring 10 of 
unsaturation51, and indicated the presence of two bromine atoms.52 Interpretation of the 13C 
NMR spectrum of 1 showed similarities to the NMR data for eudistomin V(3).53 Careful 
analysis of 1D and 2D NMR data (Table 1, Figure 5) suggested 1 contained the sub-unit 1-
methylpyrrolidine instead of 3,4-dihydro-2H-pyrrole found in eudistomin V(3) to yield 
eudistomin Z1(1) a new 6,7-dibromo-1-(1-methylpyrrolidin-2-yl)-9H--carboline. A good 
correlation between experimental and predicted 13C NMR data (R2= 0.9991) provides 
additional evidence that the proposed structure is correct (Figure S16).54 The absolute 
configuration of Z1 has yet to be determined. 
 Compound 2 (eudistomin Z2) showed a HRESIMS ion at m/z 426.0174, [M+H]+ (Δ 0.2 ppm) 
(Figure S21) for the expected molecular mass for C17H21Br2N3, and requiring 8 of 
unsaturation, and indicated the presence of two bromine atoms as found in 1. Closer inspection 
of 13C NMR data indicated similarities to compound 1 (eudistomin Z1), and eudistomins V 
(3).53 Careful analysis of 1D and 2D NMR (Table 1, Figures 5) data suggested 2 had lost 
unsaturation between N-2 and C-3 as found in 1, but N-2 had gained a methyl group yielding 
eudistomin Z2 (2), a new 6,7-dibromo-1-methylpyrrolidin-2-yl)-2,3,4,9-tetrahydro-1H--
carboline. A good correlation between experimental and predicted 13C NMR data (R2= 
4a 130.0, C     107.9, C     
4b 123.1, C     127.5, C     
5 127.2, CH  8.60, s 
  
4a, 6, 7, 8a 123.1, CH 7.79, s 
  
4a, 6, 7, 
8a 
6 115.8, C  
  116.4, C     
7 125.1, C     113.7, C     
8 117.7, CH 7.99, s  4b, 6, 7, 8a 116.6, CH 7.69, s  4b, 6, 7 
8a 141.9, C     136.4, C     
9a 134.9, C     130.8, C     
10 69.8, CH 5.07, ovlp   70.4, CH 3.80, m  14 
11 31.9, CH2 2.89, m 12  28.7, CH2 2.28, m 12  
12 23.5, CH2 
2.37, ovlp 
2.20, ovlp 
11, 13  
23.5, CH2 2.20, m 
11, 13  
13 57.0, CH2 
3.97, m 
 3.44, m 
12  
57.0, CH2 3.66, m 
12 14 
14 40.5, CH3  2.99, S  10 42.1, CH3 3.00, s  10, 13 
15     40.1, CH3 2.55, s  1, 3 
11 
 
0.9974)54 provides additional evidence that the proposed structure is correct (Figure S22). The 
absolute configuration of Z2 has yet to be determined.  
 
 
Figure 5. COSY and HMBC correlations for compounds 1 and 2  
 
Case Study 2 - Tavarua-2. This case study describes the isolation and characterisation of two 
novel nucleosides, that were predicted to be known based on matching masses in 
PharmaSeaDB. This perhaps underlines one of the limitations of this technique, where 
matching masses in the database could eliminate compounds with the same mass or molecular 
formula but possess different chemical structures. Tavarua-2, a pink mottled tunicate, (Figure 
S61) was collected at a depth of 20 m from the island of Tavarua (17.863S, 177.192E), Fiji 
Islands (Table S38). Tavarua-2 has been assigned to the family Didemnidae based on 
morphological and 18S rDNA sequence analysis (Supporting Information Part C). A voucher 
specimen (USP12338) has been deposited at the South Pacific Regional Herbarium, University 
of the South Pacific, Suva, Fiji. Tavarua-2-50, an SPE fraction of Tavarua-2 (eluted with 50% 
MeOH-H2O; sample novelty = 0.15), contained 11 potentially new compounds (Table S32). 
The identity of the dominant compound (m/z = 522, Figure S45) was of interest to us, as the 
proton NMR profile (Figure S1) did not match any of the predicted34 1H NMR profiles of the 
MS-matched compounds in PharmaSeaDB. A recalculation of the metric data using a narrower 
mass range (0.0001 Da (0.2 ppm at m/z of 500)) showed the mass was not in PharmaSeaDB 
(Figure S43, Table S44) warranting full structural investigation. HPLC purifications of this 
fraction yielded compounds 4 and 5. The molecular formula of 4 (Tavarua deoxyriboside A) 
was established by HRESIMS (Figure S5) as C26H24N3O9, and suggested 17 of unsaturation. 
The 13C data extracted from HSQC55 and HMBC32,56 NMR spectra indicated the presence of 
26 carbons (Table 2) in the form of one methyl group (C 11.8), 2 sp3 methylenes (C  37.1, 
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63.5), 9 sp2 methines (C  131.7, 131.7, 115.8, 115.8, 136.7, 105.8, 112.5, 112.3, 133.0), 3 sp3 
methines (C  85.6, 83.1, 75.1), 7 sp2 non-protonated carbons (C  120.1, 162.5, 104.6, 126.8, 
131.4, 152.6, 110.7), two amide carbonyl (C  164.7, 150.9), and two ester carbonyl (C  164.7, 
165.9) groups. 
 
Use of 1D and 2D NMR data (Figures S1-S4) enabled the construction of four substructures 
(Figure 6). The presence of a 2’-deoxy ribose unit was defined by COSY correlations: H-1’ 
and the non-equivalent CH2 protons (H-2’A and H-2’B); H-2B’ and H-3’ and between H-3’ 
and H-4’ (Substructure B, Figure S3). 13C chemical shifts of this pentose moiety are very 
similar to those found for 3-acetyl-5-methyl-2’deoxyuridine previously isolated from a marine 
sponge derived culture of Streptomyces microflavus.57  Long range HMBC correlations (Figure 
S4) between the sp2 methine at H 7.39 ppm to the two carbonyls at C 164.7 and 150.9 ppm, 
between the methyl group at H 1.42 ppm and the amide carbonyl at C 164.7 ppm suggested 
the presence of a thymine moiety in the structure of 4 (substructure A).  
 
Table 2. NMR Spectroscopic Data (600/150 MHz, CD3OD) for Tavarua Deoxyriboside A (4) 
 
pos. Ca, type H (J in Hz) COSY  
HMBC  
1H→13C 
2 150.9, C       
4 164.7, C       
13 
 
5 110.8, C       
6 136.7, CH 7.39, d (1.2)   1’, 2, 4 
7 11.8, CH3 1.42, s   4, 5, 6 
1' 85.6, CH 6.40, dd (8.7, 5.8)   2’a, 2’b  2’ 
2' 37.1, CH2 a: 2.62, m 
b: 2.49, m 
1’, 2’b, 3’ 
2’a 
1', 3' 
3' 75.1, CH 5.72, bm 4', 2’b 1', 2', 1’’ 
4' 83.1, CH  4.51, m 3'   
5’ 
63.5, CH2 a: 4.91, ovlp 
b: 4.52, dd (12.1, 3.6) 
5’b 
5’a  
1'' 164.7, C       
2'' 104.6, C       
3'' 126.8, C       
4'' 105.8, CH 7.51, d (2.4)  6’’ 5'', 10’’ 
5'' 152.6, C       
6'' 112.5, CH 6.78, dd (8.8, 2.4) 7'', 4’’ 5'', 2’’ 
7'' 112.3, CH 7.30, d (8.8) 6'' 5'' 
8'' 131.4, C       
9''         
10'' 133.0, CH 7.98, s   2'', 3'' 
1''' 165.9, C       
2''' 120.1, C       
3'''/7’’’ 131.7, CH 7.95, d (8.8) 4''' 1''', 5’’’ 
4'''/6’’’ 115.8, CH 6.86, d (8.8) 3''' 5''', 2’’’ 
5''' 162.5, C       
Ovlp = overlap 
aCarbons extracted from 2D NMR (HSQC and HMBC) data 
 
Chemical shifts and integration of the coupled aromatic sp2 methines (H 7.95, 6.86 ppm, J = 
8.8 Hz)  suggested the presence of a para-hydroxy-substituted benzene ring (substructure C).58 
COSY correlations between the sp2 methine at H 7.30, 6.78, and 7.51 ppm; HMBC 
correlations between the sp2 carbon at C 152.6 ppm and the methine at H 7.30 ppm confirmed 
the presence of a 5-hydroxy-1H-indole-3-carboxylic acid moiety (substructure D). The four 
substructures were assembled based on long range HMBC correlations. A HMBC correlation 
between the sp2 carbon at 136.7 ppm (C-6) and the methine at 6.40 ppm (H-1’) established the 
link between substructures A and B. Thymidine-2’-deoxyriboside (substructures A and B) is 
well established in marine natural products.57,59,60 
14 
 
 
Figure 6. Substructures A-D of Tavarua deoxyriboside A (4) with COSY and HMBC 
correlations. 
An HMBC correlation between C-1’’ and the proton at H-3’ established the link between 
substructures B and D. Establishing HMBC correlations between fragment B and C proved 
difficult, as HMBC correlations in fragment C were all internal. Nevertheless, the link was 
established by MS/MS fragmentation data as shown in (Figure S6), providing further evidence 
of a new thymidine-2’-deoxyriboside nucleoside. Additional proof for the structure of Tavarua 
deoxyriboside A was performed by comparing predicted and experimental 13C NMR data. 
Predicted 13C NMR data was performed using the ACD/Structure Elucidator Suite utilising the 
HOSE algorithm.61 This strategy has been shown to be effective in predicting correct structures 
of natural products.32,54 A good correlation (R2 = 0.9991) was obtained suggesting that the 
proposed planar structure for Tavarua deoxyriboside A was correct (Figure 7). 
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Figure 7. Experimental vs predicted 13C NMR data for Tavarua deoxyriboside A (4). 
The relative configurations at positions C-1’, C-3’ and C-4’ in 4 have been assigned based on 
observed 2D ROESY correlations (Figure S7) between H-2b’ (H 2.49) and H-6 (H 7.39), H-
1’ (H 6.40) and H3’ (H 5.72), and between H-3’ and H-4’(H 4.51). Weak correlations were 
observed between H2b’ and both H-1’ and H-3’. The data is consistent with a deoxyribose 
linked α to N-1. Figure S8 shows the calculated global minimum energy conformation for 
compound 4 using ChemBio3D Ultra 12.0.62  
The absolute configuration of the deoxyribose unit in 4 for the positions C-1’, C-3’and C-4’ 
has been determined to be S,R,R based on comparison of experimental electronic circular 
dichroism (ECD) spectrum with that computationally derived using the Avogadro molecular 
modelling software version 1.1.1 and energy minimized with the MMFF94 force field.63,64 
Calculation of all eight stereoisomers yielded S,R,R as the best fit (Supporting Information Part 
B). 
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Figure 8. Overlay of calculated (blue) over experimental (black) ECD spectra for Tavarua 
deoxyribose (4) indicating the S,R,R configuration at positions C-1’,C-3’,C-4’. 
 
Tavarua deoxyriboside B (5) showed a molecular formula of C25H22N3O9 suggesting 17 
degrees of unsaturation. The LCMS data suggested the loss of a methyl group from the 
structure of 4 (Figure S9). This was confirmed by inspection of the 1H NMR spectrum (Figure 
S10) of 5 which had lost the proton singlet at H 1.40 ppm in 4 and replaced by a proton at H 
5.45 ppm (J =8.1 Hz) yielding a new pyrimidine-2’-deoxyribose nucleoside (5). 
Compounds containing the indole-3-carbonyl motif in natural products are not common and its 
presence commonly can be found in a small group of natural products, such as indolyl-3-
carbonyl-alpha-L-rhamnopyranoside from Streptomyces sp. GT 06115065 and 1H-Indole-3-
carbothioic acid S-methyl ester from the marine bacterium Oceanibulbus indolifex Hel 45.66 
Nucleosides containing benzoyl ester motifs have been previously isolated from the marine 
fungus Aspergillus versicolor derived from the gorgonian Dichotella gemmacea67 and related 
compounds from the marine ascidian Atriolum robustum.68 
 
 
CONCLUSION 
The study has shown that a simple, sample prioritisation approach, based on calculated metric 
scores can successfully identify samples that contain potentially new or novel compounds as it 
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resulted in the isolation and structure elucidation of two new eudistomin-analogues and two 
new nucleosides. The study has also highlighted a general limitation of the method, where new 
or novel compounds could be missed if they share the same HRMS data.69 We are currently 
working on improving the accuracy of this strategy by including MS/MS, and predicted HPLC 
retention time data,27 to provide better and reliable identification of known compounds. 
Molecular networking70 based on MS/MS has been used successfully to identify compound 
families that can be helpful as an additional prioritization filter. For compounds that are not in 
the integrated database statistical analysis like use of PCA can help identify compounds that 
are most interesting.71 Nevertheless the strategy discussed in this paper has demonstrated the 
importance of sample prioritisation for rapid discovery of new or novel natural products, 
particularly when working with larger sample sets. 
 
EXPERIMENTAL SECTION 
General Experimental Procedures. The optical rotation was recorded using a Bellingham & 
Stanley, Model ADP410 Polarimeter at 589 nm at 25 C. UV spectra were recorded on a 
photodiode array (DAD)-HPLC system. ECD spectra were obtained using a Jasco J-810 
spectropolarimeter72 at 20 C. The sample was measured at a concentration of 0.2 mg/mL 
dissolved in spectral grade methanol using a 0.5 mm pathlength quartz cuvette. IR spectra were 
recorded on a Perkin Elmer UATR Two, Model L1600300. NMR data, both 1D and 2D were 
recorded on a Bruker AVANCE III HD Prodigy TCI Cryoprobe at 600 and 150 MHz for 1H 
and 13C respectively. This instrument was optimized for 1H observation with 
pulsing/decoupling of 13C and 15N with 2H lock channels equipped with shielded z-gradients 
and cooled preamplifiers for 1H and 13C.  The 1H and 13C chemical shifts were referenced to 
the solvent signals (δH 3.31 and δC 49.00 in CD3OD). High resolution mass spectrometry data 
were measured using a Thermo Fisher Scientific LTQXL-Discovery Orbitrap73 coupled to an 
Accela UPLC-DAD system. The following conditions were used for mass spectrometric 
analysis: capillary voltage 45 V, capillary temperature 320 °C, auxiliary gas flow rate 10 -20 
arbitrary units, sheath gas flow rate 40-50arbitrary units, spray voltage 4.5 kV, mass range 100-
2000 amu, resolution 30,000 for MS and 7,500 for MS/MS. Solid phase extractions (SPE) were 
performed using Phenomenex74 C18 cartridges (Strata C18-E, 55um, 70Å). Semi-preparative 
HPLC purifications were performed using an Agilent75 1100 HPLC system consisting of a 
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binary pump, degasser, photodiode array detector (DAD), and a preparative fraction collector. 
All solvents were of HPLC grade. 
LCMS Analysis. Each fraction (56 in total) was prepared in 100% MeOH to produce a 0.5 
mg/mL solution with 4 L injected by HPLC, and then post-column split (3:4 (v:v), MS:DAD). 
Analysis by LCMS was carried out using polarity switch mode where only the positive mode 
was under high resolution. Both the MS/MS and negative mode were measured at 7,500 peak 
resolution respectively. HPLC separations were carried out on an Agilent Technologies75 
Poroshell 120, EC-C18, 2.1 x 100 mm at 0.4 mL/min flow rate. The solvents used: A (100% 
CH3CN + 0.1% formic acid), B (100% H2O + 0.1% formic acid) on a solvent gradient system 
from 0 to 100% CH3CN in 25 min and flushed with 100% B for another 5 min, followed by a 
5 min equilibration time before the next injection. 
Data Analysis and Database Searching. Each LCMS data set (RAW file format) was loaded 
into ACD/Spectrus DB Enterprise (Figure S23), and a query was created through 
ACD/IntelliXtract (IX.mcr) using optimized data processing parameters. This was followed by 
screening of the matrix database (MatrixDB) to identify matrix contaminants, followed by 
screening of the 24,618 compounds in PharmaSeaDB, and subsequent calculations performed 
to generate metrics output files. 
Sample Collection. A collection of 8 marine sponges and 6 tunicates was collected from the 
west coast of Viti Levu, Fiji Islands (-17.839 S, 177.199 E) in March of 2009 (Table S38). 
Subsamples for DNA analysis were prepared and stored in RNAlater stabilization solutions.76 
Samples were stored in plastic containers, preserved in 100% MeOH and shipped to the 
University of Aberdeen where they were stored at 4 C before processing for analysis. 
Taxonomic identifications of Tavarua8 (Tava8) and Tavarua2 (Tava2) were carried out using 
morphological and molecular DNA approaches (Supplementary Information C). Sequences for 
Tava8 and Tava2 have been deposited at the European Nucleotide Archive (ENA)77 with AC 
numbers LR136919-20, LR136924, and LR136942 (Tables: S64, S65). 
Extraction and Isolation. Samples were extracted with MeOH (3x) followed by CH2Cl2 (3x), 
placed in glass vials and dried under the flow of nitrogen gas at 39 C using a Microlab Aarhus 
A/S Supertherm mini-oven evaporator.78 The dried samples were then fractionated into four 
fractions based on polarity using C18 solid phase extraction (SPE) cartridges. After column 
conditioning as recommended by Phenomenex74 each sample was loaded to the SPE cartridge 
and then flushed with 100% H2O to remove salts and highly polar compounds.
46 This was 
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followed by flushing with 25% MeOH in H2O (SPE-25), followed by 50% MeOH/H2O (SPE-
50), then by 100% MeOH (SPE-100). Finally, the column was flushed with 100% MeOH 
containing 0.05% TFA (SPE-100 + TFA). All fractions were dried as before and stored at 4 C 
awaiting analysis. 
Case Study 1. The fraction SPE-100% MeOH (Tavarua-8) was purified using an ACE 5 C18 
HL, 250 x 100 mm column79 and a solvent gradient system from 95% H2O in MeOH to 100% 
MeOH from 0-30 min at a flow rate of 2.0 mL/min yielding the new compounds: 1 (1.4 mg), 
2 (0.9 mg). 
Case Study 2. The SPE-50 fraction of Tavarua-2 was purified using an ACE 5 C18 HL, 250 x 
100 mm HPLC column and a solvent gradient system from 0 to 100% CH3CN containing 
0.05% TFA in 30 min at a flow rate of 1.5 mL/min to yield 4 (1.2 mg) and 5 (0.2 mg).  
 
Eudistomin Z1 (1): Light brownish oil;  UV (MeOH) max 400, 370, 300, 250 nm (Figure S50); 
IR (MeOH) max 3300, 2870, 1580, 1430, 1155, 1310, 1150 cm-1 ; 1H and 13C NMR data 
(CD3OD, 600 and 150 MHz, respectively), Table 1; HRESIMS m/z 407.9702 [M+H]
+ 
(calculated for C16H15Br2N3 , 407.9711,  = 0.8 ppm) (Figure S15). 
Eudistomin Z2 (2): Light brownish oil; UV (MeOH) max 300, 250 nm (Figure S51); IR 
(MeOH) max  3400, 2900, 1600, 1535, 1470, 1295, 1090 cm-1; 1H and 13C NMR data (CD3OD, 
600 and 150 MHz, respectively), Table 1; HRESIMS m/z 426.0174, [M+H]+ (calculated for 
C17H21Br2N3, 426.0181, Δ = 0.2 ppm) (Figure S21). 
Tavarua deoxyriboside A (4): Colourless oil; []D20 -110 (c 0.11 g/100 mL, MeOH); UV 
(MeOH-H2O) max 216, 260, 300 (Figure S46); ECD (0.0004 M, MeOH)  () 220 (-0.8), 230 
(-0.2), 243 (-1.2), 257 (1.6), 285 (-1.5) nm (Figure S49); IR (MeOH) max 3257, 2925, 2854, 
1686, 1608, 1516, 1441, 1374, 1354,1269, 1203, 1165, 1099, 1052, 1099, 853, 772 (Figure 
S48); 1H and 13C NMR data (CD3OD, 600 and 150 MHz, respectively), see Table 2; HRESIMS 
m/z 522.1508 [M+H]+ (calculated for C26H24N3O9, 522.1507, Δ = 0.47 ppm) (Figure S5).  
 
Tavarua deoxyriboside B (5): Colourless oil; UV (MeOH)/H20 max 216, 260, 351 (Figure S47). 
1H data (CD3OD, 600 MHz)  7.93 (2H, d, J = 8.8 Hz, H3’’’/H7’’’), 7.93 (1H, s, H-10’’), 7.70 
(1H, d, J = 8.1 Hz, H-6), 7.50 (1H, d, J =2.3 Hz, H-4’’), 7.29 (1H, d, J = 8.8 Hz, H-7’’), 6.84 
(1H, d, J = 8.8 Hz, H-4’’’/H6’’’), 6.78 (1H, dd, J = 8.5, 2.5 Hz, H-6’’), 6.34 (1H, dd, J = 8.1, 
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6.3 Hz, H-1’), 5.66 (1H, bm, H-3’), 5.45 (1H, d, J = 8.1 Hz, H-5), 4.77 (1H, dd, J = 12.1, 3.7, 
H-5a’), 4.64 (1H, dd, J = 12.1, 3.7, H5b’), 4.52 (1H, overlap, H-4’), 2.64 (1H, m, H -2a’), 2.49 
(1H, m, H-2b’), (Figure S10); HRESIMS m/z 508.1355 [M+H]+ (calculated for C25H22N3O9, 
508.1351, Δ = -0.82 ppm) (Figure S9). 
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